Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
Appointed director
CC transcript
CATALYST BIOSCIENCES, INC. (CBIO) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/07/2021 GN Catalyst Biosciences to Present at the 20th Annual Needham Virtual Healthcare Conference
03/04/2021 GN Catalyst Biosciences Reports Fourth Quarter and Full-Year 2020 Operating & Financial Results and Provides a Corporate Update
02/11/2021 GN Catalyst Biosciences Announces Partial Exercise and Closing of Over-Allotment Option in Public Offering of Common Stock
02/03/2021 GN Catalyst Biosciences Presents Pre-clinical SQ Treatment of Bleeds Data from its Marzeptacog alfa (activated) (MarzAA) Program at the 14th Annual EAHAD Congress
01/29/2021 GN Catalyst Biosciences Announces Closing of Public Offering of Common Stock
01/27/2021 GN Catalyst Biosciences Announces Pricing of Public Offering of Common Stock
01/26/2021 GN Catalyst Biosciences Announces Proposed Public Offering of Common Stock
01/20/2021 GN Catalyst Biosciences Announces Poster Presentations at the EAHAD 2021 Virtual Congress
12/07/2020 GN Catalyst Biosciences Presents Crimson 1 Phase 3 Study Design at the 62nd Annual American Society of Hematology Conference
12/03/2020 GN Catalyst Biosciences Hosting Research & Development Call on Systemic Complement Regulator Programs
11/24/2020 GN Catalyst Biosciences to Present at 32nd Annual Piper Sandler Virtual Healthcare Conference
11/05/2020 GN Catalyst Biosciences Reports Third Quarter 2020 Operating & Financial Results and Provides a Corporate Update
10/14/2020 GN Catalyst Biosciences Receives US Patent for its Anti-Complement Factor 3 Portfolio of Engineered Proteases
09/25/2020 GN Catalyst Biosciences to Present at the Stifel Immunology and Inflammation Summit
08/06/2020 GN Catalyst Biosciences Reports Second Quarter 2020 Operating & Financial Results and Provides a Corporate Update
07/01/2020 GN Catalyst Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06/22/2020 GN Catalyst Biosciences Announces Closing of Public Offering of Common Stock
06/22/2020 GN Catalyst Biosciences Appoints Charles Democko, Senior Vice President, Regulatory Affairs
06/19/2020 GN Catalyst Biosciences Presents Preclinical FIX Gene Therapy Data in an Oral Presentation at the World Federation of Hemophilia Virtual Summit 2020
06/17/2020 GN Catalyst Biosciences Announces Proposed Public Offering of Common Stock
06/15/2020 GN Catalyst Biosciences Appoints Clinton Musil as Chief Financial Officer
06/15/2020 GN Catalyst Biosciences Presents Positive Final Data from its Phase 2b Trial of Subcutaneous Dalcinonacog Alfa (DalcA) at the World Federation of Hemophilia Virtual Summit 2020
06/10/2020 GN Catalyst Biosciences Completes MarzAA Pharmacokinetic & Pharmacodynamic Study
06/08/2020 GN Catalyst Biosciences Announces Oral and Poster Presentations at the World Federation of Hemophilia Virtual Summit 2020
04/28/2020 GN Catalyst Biosciences Receives Patent in the European Union for Its Factor IX Portfolio
04/21/2020 GN Catalyst Biosciences Completes Phase 2b Trial of Subcutaneous Factor IX Dalcinonacog Alfa (DalcA)
02/24/2020 GN Catalyst Biosciences to Present at the Cowen Healthcare Conference
02/20/2020 GN Catalyst Biosciences Reports Fourth Quarter and Full-Year 2019 Operating & Financial Results and Provides a Corporate Update
01/17/2020 GN Catalyst Biosciences Announces Addition of Geoffrey Shiu Fei Ling, M.D. and Sharon Tetlow to Board of Directors
11/07/2019 GN Catalyst Biosciences Reports Third Quarter 2019 Operating & Financial Results and Provides a Corporate Update
09/05/2019 GN Catalyst Biosciences to Present at the 2019 ASBMB Symposium on Serine Proteases in Pericellular Proteolysis and Signaling Conference
08/29/2019 GN Catalyst Biosciences Announces Transition of Chief Financial Officer
08/16/2019 GN Catalyst Biosciences to Present at the 2019 Hemophilia Drug Development Summit
07/08/2019 GN Catalyst Biosciences Meets the Primary Endpoint of Reduction in Annualized Bleeding Rate in the Phase 2 Trial of Subcutaneous Marzeptacog Alfa (Activated) in Patients with Hemophilia A or B with Inhibitors
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy